$ADIA News

Adia Med Reports No Serious Adverse Events in First Cohort of Pediatric Autism Study; Enrollment Continues

Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash

Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position

Adia Med Partners with Live Oak Health (dba QCM Biologics) as Distributor and Sells 30% Stake in Adia Labs for $1.5 Million

Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line

Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products

Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment

Nasdaq Shareholder Requirements Just Verified By Adia Med

From Full Sail to Full-Scale: Adia Med Inc. Assembles Intern Social Media Team

Adia Med Inc. Engages Lucosky Brookman LLP as Legal Counsel for Planned NASDAQ Uplisting

Adia Med Delivers Record Q2 Results: $485K Revenue, First Net Profit, and Nearly Matches Full-Year 2025 Revenue in First Half

Adia Med Partners with Full Sail University; CEO Larry Powalisz to Present Company and Explore Student Assistance with SEO, Social Media, and Marketing

Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration Opportunities

Adia Med Completes Phase 1 and Formally Launches Phase 2 of Autism Spectrum Disorder Clinical Study

Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website

Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ

Adia Nutrition to Trade as Adia Med Inc. After Lightning-Fast FINRA Review

Adia Nutrition Inc. Enters FINRA Home Stretch for Corporate Name Change to Adia Med Inc.

Adia Med Finds Another Unicorn

Adia Med Improves Quality of Care with Advanced Ultrasound-Guided IV Training